Prevention of hepatocellular carcinoma recurrence: Actuality and perspectives

Hepato-Gastroenterology

Volumn 49, Issue 43, 2002, Pages 87-90

  Takayama, Tadatoshi ^a   Makuuchi, Masatoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adoptive immunotherapy; Cancer recurrence; Hepatic resection; Hepatocellular carcinoma

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; IMMUNOTHERAPY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HEPATECTOMY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036213429     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Rising incidence of hepatocellular carcinoma in the United States
2. Early hepatocellular carcinoma as an entity with a high rate of surgical cure
3. Treatment of hepatocellular carcinoma
4. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis
5. Hepatic resection for hepatocellular carcinoma: An audit of 343 patients
6. Recurrence of hepatocellular carcinoma after surgery
7. An anlysis of 412 cases of hepatocellular carcinoma at a Western center
8. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
9. Hematogenous spreading of hepatocellular carcinoma cells: Possible participation in recurrence in the liver
10. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
11. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma
12. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma
13. Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies: A preliminary report
14. Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer: Characterizations and clinical utilization
15. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2
16. A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients
17. Cytotoxic activity of CD4+ T cells against autologous tumor cells
18. Adjuvant adoptive immunotherapy against hepatocellular carcinoma
19. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial
20. Current status of adoptive immunotherapy of cancer
21. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma
22. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial
23. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: A prospective randomized study of hepatitis C virus-related liver cancer
24. Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: A randomized, controlled trial
25. Maintenance interferon for chronic hepatitis C: More issues than answers?